市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | ImmunityBio, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 1.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.38 |
|
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 74.11% |
| 机构持股比例 | 9.33% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Hrt Financial Lp | 31 Mar 2026 | 3,925,446 |
| Woodline Partners Lp | 31 Mar 2026 | 3,447,346 |
| Voloridge Investment Management, Llc | 31 Mar 2026 | 2,927,552 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 23.00 (D. Boral Capital, 231.89%) | 购买 |
| 中 | 18.00 (159.74%) | |
| 低 | 13.00 (BTIG, 87.59%) | 购买 |
| 平均值 | 18.00 (159.74%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 8.14 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| BTIG | 12 Mar 2026 | 13.00 (87.59%) | 购买 | 7.82 |
| D. Boral Capital | 09 Mar 2026 | 23.00 (231.89%) | 购买 | 8.45 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合